Dolutegravir news

All news on Dolutegravir (also known as Tivicay and GSK1349572): plants, production capacities, investments and involved companies.

29 July 2026

ViiV Healthcare: Cabenuva superior to daily oral therapy in adolescents at AIDS 2026

LATA shows superiority in adolescents; OPERA real‑world suppression comparable to oral regimens; cabotegravir injections rated better than lenacapavir; EXTEND 4M tests 4‑month formulation.
28 July 2026

GSK Q2: strong core results, R&D acceleration and 20+ Phase III starts in 2026

Core operating profit +7% and core EPS +9%; sales up, driven by Specialty Medicines and Vaccines; new R&D centre and a 3-year £1.9bn annual savings target to fund late-stage pipeline.
9 June 2026

GSK to acquire Nuvalent for $10.6 billion

Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.

Who will be producing Dolutegravir in the future?

Find out with chemXplore Alpha

Learn more